NTLA vs. BEAM

Last updated Apr 2, 2026

Compare and contrast key facts about Intellia Therapeutics, Inc. (NTLA) and Beam Therapeutics Inc. (BEAM).

Performance

NTLA vs. BEAM - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Intellia Therapeutics, Inc. (NTLA) and Beam Therapeutics Inc. (BEAM). The values are adjusted to include any dividend payments, if applicable.

NTLA vs. BEAM - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020
NTLA Intellia Therapeutics, Inc.	47.61%	-22.90%	-61.76%	-12.61%	-70.49%	117.35%	284.72%
BEAM Beam Therapeutics Inc.	-12.63%	11.77%	-8.89%	-30.40%	-50.92%	-2.39%	335.41%

Fundamentals

Market Cap NTLA : $1.44B BEAM : $2.54B
EPS NTLA : -$3.84 BEAM : -$0.78
PB Ratio NTLA : 2.14 BEAM : 2.05
Total Revenue (TTM) NTLA : $0.00 BEAM : $25.63M
Gross Profit (TTM) NTLA : -$34.30M BEAM : -$284.71M
EBITDA (TTM) NTLA : -$322.22M BEAM : -$352.98M

Returns By Period

In the year-to-date period, NTLA achieves a 47.61% return, which is significantly higher than BEAM's -12.63% return.

NTLA

• 1D: 3.51%
• 1M: -14.05%
• YTD: 47.61%
• 6M: -29.26%
• 1Y: 99.40%
• 3Y*: -29.12%
• 5Y*: -30.19%
• 10Y*: —

BEAM

• 1D: 1.64%
• 1M: -15.58%
• YTD: -12.63%
• 6M: 0.37%
• 1Y: 37.34%
• 3Y*: -7.52%
• 5Y*: -21.20%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

NTLA vs. BEAM — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

NTLA

NTLA Risk / Return Rank: 70
NTLA Sharpe Ratio Rank: 73
NTLA Sortino Ratio Rank: 72
NTLA Omega Ratio Rank: 75
NTLA Calmar Ratio Rank: 66
NTLA Martin Ratio Rank: 61

BEAM

BEAM Risk / Return Rank: 58
BEAM Sharpe Ratio Rank: 58
BEAM Sortino Ratio Rank: 62
BEAM Omega Ratio Rank: 58
BEAM Calmar Ratio Rank: 56
BEAM Martin Ratio Rank: 55

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

NTLA vs. BEAM - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Intellia Therapeutics, Inc. (NTLA) and Beam Therapeutics Inc. (BEAM). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	NTLA	BEAM	Difference
Sharpe ratio Return per unit of total volatility	0.99	0.49	+0.50
Sortino ratio Return per unit of downside risk	1.74	1.30	+0.44
Omega ratio Gain probability vs. loss probability	1.25	1.15	+0.10
Calmar ratio Return relative to maximum drawdown	1.22	0.63	+0.59
Martin ratio Return relative to average drawdown	2.17	1.39	+0.77
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

NTLA vs. BEAM - Sharpe Ratio Comparison

The current NTLA Sharpe Ratio is 0.99, which is higher than the BEAM Sharpe Ratio of 0.49. The chart below compares the historical Sharpe Ratios of NTLA and BEAM, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	NTLA	BEAM	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.99	0.49	+0.50
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.38	-0.28	-0.09
Sharpe Ratio (All Time) Calculated using the full available price history	-0.06	0.05	-0.12

Correlation

The correlation between NTLA and BEAM is 0.71, which is considered to be high. That indicates a strong positive relationship between their price movements. Having highly-correlated positions in a portfolio may signal a lack of diversification, potentially leading to increased risk during market downturns.

Dividends

NTLA vs. BEAM - Dividend Comparison

Neither NTLA nor BEAM has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

NTLA vs. BEAM - Drawdown Comparison

The maximum NTLA drawdown since its inception was -96.45%, which is greater than BEAM's maximum drawdown of -89.12%. Use the drawdown chart below to compare losses from any high point for NTLA and BEAM.

Drawdown Indicators

	NTLA	BEAM	Difference
Max Drawdown Largest peak-to-trough decline	-96.45%	-89.12%	-7.33%
Max Drawdown (1Y) Largest decline over 1 year	-71.27%	-38.15%	-33.12%
Max Drawdown (5Y) Largest decline over 5 years	-96.45%	-89.12%	-7.33%
Current Drawdown Current decline from peak	-92.49%	-81.87%	-10.62%
Average Drawdown Average peak-to-trough decline	-56.43%	-59.31%	+2.88%
Ulcer Index Depth and duration of drawdowns from previous peaks	39.98%	17.25%	+22.73%

Volatility

NTLA vs. BEAM - Volatility Comparison

Intellia Therapeutics, Inc. (NTLA) and Beam Therapeutics Inc. (BEAM) have volatilities of 17.93% and 17.48%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	NTLA	BEAM	Difference
Volatility (1M) Calculated over the trailing 1-month period	17.93%	17.48%	+0.45%
Volatility (6M) Calculated over the trailing 6-month period	85.04%	53.97%	+31.07%
Volatility (1Y) Calculated over the trailing 1-year period	101.32%	77.28%	+24.04%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	80.73%	75.45%	+5.28%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	78.27%	80.54%	-2.27%

Financials